Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfunction

摘要

The present invention provides a method for the treatment of a condition in a subject arising from or associated with CFTR dysfunction, said method comprising administering to said subject an effective amount of a CFTR modulator together with an effective amount of an alginate oligomer. In certain embodiments said condition is cystic fibrosis (CF), non-compound CFTR gene mutation heterozygosity, abnormal mucus clearance in the respiratory tract and/or breathing difficulties resulting from chronic particulate inhalation, COPD, chronic bronchitis, emphysema, bronchiectasis, asthma or chronic sinusitis, or a complication thereof.